Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2,3,7-Trisubstituted pyrazolo[1,5-d][1,2,4]triazines: functionally selective GABAA alpha3-subtype agonists.

Robert W Carling1, Michael G N Russell, Kevin W Moore

  • 1Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK. robert.carling@virgin.net

Bioorganic & Medicinal Chemistry Letters
|April 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the psychosocial impact of prosthetic rehabilitation in patients with head and neck cancer: A scoping review.

The Journal of prosthetic dentistry·2026
Same author

Ovine forestomach matrix as a novel adjunct to promote healing of low output enterocutaneous fistulae in high-risk surgical patients.

Trauma case reports·2026
Same author

SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways.

Drug design, development and therapy·2026
Same author

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination.

Clinical pharmacology and therapeutics·2026
Same author

Accuracy of glomerular filtration rate estimation based on creatinine and cystatin C for monitoring moderate chronic kidney disease in adults: prospective, longitudinal cohort study.

BMJ (Clinical research ed.)·2026
Same author

Novel positive allosteric modulators of alpha 5 subunit-containing GABA<sub>A</sub> receptors (α5-GABA<sub>A</sub>Rs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia.

Schizophrenia research·2026

New synthetic methods enable access to novel pyrazolo[1,5-d][1,2,4]triazines. These compounds target the GABA(A) benzodiazepine site, with some showing selective activity at alpha3 receptors.

Area of Science:

  • Medicinal Chemistry
  • Organic Synthesis
  • Neuroscience

Background:

  • The GABA(A) receptor is a key target for central nervous system drugs.
  • Benzodiazepines are known ligands for the GABA(A) receptor's benzodiazepine binding site.
  • Developing novel ligands with specific receptor subtype selectivity is crucial for improved therapeutics.

Purpose of the Study:

  • To develop novel synthetic routes for previously inaccessible 2,3,7-trisubstituted pyrazolo[1,5-d][1,2,4]triazines.
  • To investigate the binding affinity of these novel compounds to the GABA(A) benzodiazepine binding site.
  • To explore functional selectivity of these analogues at different GABA(A) receptor subtypes.

Main Methods:

  • De novo synthesis of pyrazolo[1,5-d][1,2,4]triazine derivatives.

Related Experiment Videos

  • Radioligand binding assays to determine affinity for the GABA(A) benzodiazepine site.
  • Functional assays to assess subtype selectivity (e.g., alpha3 vs. alpha1 containing receptors).

    • Main Results:

    • Successful synthesis of a novel series of 2,3,7-trisubstituted pyrazolo[1,5-d][1,2,4]triazines.
    • Compounds demonstrated high affinity for the GABA(A) benzodiazepine binding site.
    • Specific analogues exhibited functional selectivity for alpha3-containing receptors over alpha1-containing receptors, with compound 32 identified as a lead.

    Conclusions:

    • The developed synthetic routes provide access to a new chemical space of pyrazolo[1,5-d][1,2,4]triazine ligands.
    • These compounds represent promising scaffolds for developing selective modulators of GABA(A) receptors.
    • The lead compound 32 warrants further investigation for potential therapeutic applications targeting specific GABA(A) receptor subtypes.